Gladdy Lab

Sarcoma Functional Genomics|Professor of Surgery, UofT|Site Lead Toronto Sarcoma Program|Surgeon-Scientist

[Gladdy Lab @GladdyLab]

Our team effort to better understand #leiomyosarcoma from molecular classification🧬,metastatic progression🔬,use of DDRi💊is out today @NatureComms! Great collaboration with #AdamShlien @SickKidsNews @OICR @PMResearch_UHN @SinaiHealth
🙏to our patients
https://t.co/otInZHWCJ7

[Steven Artandi, MD, PhD @SCIDirector]

An international framework, developed by a global team including SCI member @cncurtis, guides clinical translation of molecular classifiers in #osteosarcoma, highlighting pre-treatment ctDNA for implementation, with other biomarkers needing validation. https://t.co/0Au4OSQvvp

[Conquer Cancer, the ASCO Foundation @ConquerCancerFd]

How do you improve outcomes in a rare, aggressive cancer with limited treatment options? At #ASCO26 this week, Dr. Mark Dickson, a Conquer Cancer-funded researcher, will deliver promising phase 3 clinical trial results on a gene-targeting therapy. Read more about this work ahead of the meeting: https://t.co/FUoSgLbThl

[C17 Council @C17Council]

Adam Shlien: An international framework for clinical translation of molecular classifiers in osteosarcoma - NPJ Precision Oncology. May 2026 https://t.co/Cepto1z2xy

[Gladdy Lab @GladdyLab]

Incredible to learn about #sustainabilty
Global leadership 🌎🌳&innovation @uoftmedicine @SustainableUofT
with @Ecosurgeon @UBC
visiting Tovee Professor
@UofTSurgery @UofTGSx
Climate and Energy change for healthcare and our U of T community

[TARPSWG @TARPSWG]

Proud to announce the new partnership between TARPSWG and @SocSurgOnc !

Together, we aim to advance global #sarcoma care through collaboration, education, and surgeon-led research in #RPS.
Looking forward to new opportunities for the international sarcoma community.

[JAMA Oncology @JAMAOnc]

A dose-reduced preoperative radiotherapy regimen (36 Gy in 18 fractions) for liposarcoma offered high local control and low rates of major late toxic effects in a phase 2 trial, supporting use in eligible patients.

#ESTRO26 @ESTRO_RT

https://t.co/E4IHYCjqJv

[Michael G. Fehlings @DrFehlings]

New publication: Viewpoint: are surgeon-scientists still worth the investment?
@UofTSpine @UofTSurgery @KBI_UHN @UofTNeuroSurge
https://t.co/cg4syP7ZwQ

[TARPSWG @TARPSWG]

Registration is now open for the #TARPSWG Semiannual Meeting 2026 in Seoul 🇰🇷
📅 November 18, 2026
📍 Seoul, South Korea
💻 In-person & remote participation available
🔗 Register here: https://t.co/trHVdcaZC2
@ctosociety @SocSurgOnc @SoMe4sarcoma #Sarcoma #RPS #SurgicalOncology

[Marco Fiore, MD, FACS, FEBSh @FioreDoc]

Highlights include:
• TARPSWG Lecture by Dirk Strauss on the future perspectives opened by prospective #RESAR registry data
• Interactive RE-LIVE surgery sessions from INT Milan and U Toronto Mount Sinai, featuring Carol Swallow, Alessandro Gronchi, Marco Fiore

[TARPSWG @TARPSWG]

#ReSurge #RetroperitonealSarcoma surgery Masterclass.

Register here https://t.co/xo0BJBhZ5D

[Marco Fiore, MD, FACS, FEBSh @FioreDoc]

Interested in #RetroperitonealSarcoma surgery?
Join #ReSurge2026, the @ESSOnews online course endorsed by @TARPSWG community.

@alegronchi @FioreDoc #CarolJSwallow #DirkStrauss

Register here: https://t.co/ZGhmLWeojk @IstTumori @SinaiHealth

[Society of Surgical Oncology @SocSurgOnc]

SSO is proud to announce our partnership with
@TARPSWG, a global network of 400+ members across 50 high-volume sarcoma centers.

This collaboration strengthens our shared commitment to advancing global collaboration, education, and surgeon-led sarcoma research.

[Dario Callegaro @DCalleMD]

The #Sarculator app update is now live!
This comes together with our @TheLancetOncol paper introducing #BayeSarc, a Bayesian sequential learning approach to refine prognostication in extremity soft tissue #sarcoma.
Paper: https://t.co/gQuFERjCqu
App: https://t.co/4mLSfv7zE3

[ACS Journal Cancer @JournalCancer]

Does regional hyperthermia add benefit to neoadjuvant chemotherapy in extremity soft-tissue #sarcoma? A new analysis of the EORTC 62961–ESHO 95 trial provides updated survival data.

Full #OpenAccess article: https://t.co/9zD1eDNOud

@Maegges79 @OncoAlert CC: @chandrajitraut

[Gladdy Lab @GladdyLab]

wonderful to have Torsten Nielsen join Sarcoma Research Rounds ⁦@pmcancercentre⁩ ⁦@SinaiHealth⁩

#synovialsarcoma #chondrosarcoma

[Trudy Wu, MD @TrudyWuMD]

Incredibly touched by this. Please take a minute to read today. An important message for physicians everywhere

[U of T CIP @UofT_CIP]

Congrats to the many CIP trainees involved with UpSurge and this paper @Bondzi23 @DavidDan_Ngn @armaan_km @KennedyAyoo @ben_li123 #sherrymahmood and others

[Sinai Health @SinaiHealth]

We’re proud to be part of the Marathon of Hope Cancer Centres Network and contribute to this national effort inspired by Terry Fox.

This Innovation Report showcases the progress made - and the impact it’s having on cancer research and care in Canada ➡️ https://t.co/uhMbTVMDqh

[Sinai Health @SinaiHealth]

Congratulations to Dr. Keiran Campbell, investigator at LTRI, on receiving the Canadian Society of Molecular Bioscience’s New Investigator Award (@CSMB_SCBM), recognizing his achievements and leadership in computational cancer biology 👏

#SinaiHealth #LTRI #CancerResearch

[CIHR @CIHR_IRSC]

Someone took the time to review your last grant. Now it’s your turn.

CIHR needs reviewers for the Spring 2026 Project Grant competition.

Say “YES” when asked.